While Vaccine Effectivity Wanes Pharma Makers Generate $1,000 Per Second plus Zero Liability in Major Markets

What defines a good vaccine? Clearly, one that lasts for at least a year—no? Flu shots typically only last a season—is this comparable? Several studies reveal that the COVID-19 vaccines wane in effectiveness, evidencing durability challenges. Whether studies in Mayo Clinic in the USA or a national study in Sweden to the recently peer-reviewed Israeli study published in Nature Communications led by KI Institute using data from Maccabi Health Services and their research arm, the Pfizer-BioNTech vaccine has been shown to wane in protective powers—from over 90% to 51% in just five or six months. That number dips below 40% within half a year, according to some of the studies. The actual durability is still not certain but mounting real-world evidence shines some light on the topic. In the meantime, the top two mRNA-vaccine producers generate combined profits of $65,000 per minute.

The most recent peer-reviewed study was conducted as the delta variant raged across Israel. Given the recent booster push, conditions appear to be stabilizing in Israel. Cases of SARS-Cov-2 infections have come substantially down. A big test for the Pfizer-BioNTech vaccine will be if infections surge ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee